Skip to content
Storytelling Co – Lifestyle
Author:
Full-Life Technologies
Full-Life Technologies Reports Encouraging Preliminary Phase 1 Safety and PSA Decline for FL-020 in mCRPC at ESMO 2026
October 23, 2026
Full-Life Technologies Reports First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand FL-261 Showing Robust Tumor Uptake, High Lesion Contrast and No Tracer-Related Serious Adverse Events in Patients with NSCLC
October 19, 2026
Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial
September 9, 2026